Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

DTIL - Precision BioSciences, Inc. So'nggi... | Finranks

Home

DTIL

(DTIL)

NCM – Real vaqt narxi. Valyuta: USD

6.02

-0.52 (-7.95%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

6.02

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 4:04 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript

Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript

Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript

Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates

Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates

Precision BioSciences (DTIL) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of a loss of $0.21 per share. This compares to a loss of $3.2 per share a year ago.

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2025, and provided a business update. “2025 was an exceptional year for Precision BioSciences marked by meaningful clinical and financial progress. We delivered on what we co.

Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent applications relating to the Company's PBGENE-HBV program. The first Notice of Allowance relates to U.S. Patent Application No. 19/347,136, tit.

Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026

Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced presentation of new preclinical study data supporting the potential long-term efficacy of PBGENE-DMD. The data presentation took place during a poster session at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference 2026 curre.

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the fourth quarter 2025 and provide a business update on March 12, 2026. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DT.

Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event

Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). The Company also announced that it will host a virtual key opinion leader (KOL) event on Tuesday.

Videolar

No Data

There is no data to display